false
0001938571
0001938571
2026-04-06
2026-04-06
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
April 6, 2026
ADAPTIN BIO, INC.
(Exact Name of Registrant as Specified in Charter)
| Delaware |
|
000-56583 |
|
88-1566415 |
|
(State or Other Jurisdiction
of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
|
3540 Toringdon Way, Suite 200, #250
Charlotte, North Carolina |
|
28277 |
| (Address of Principal Executive Offices) |
|
(Zip Code) |
(888)-609-1498
(Registrant’s telephone number, including
area code)
N/A
(Former Name or Former Address, if Changed Since
Last Report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act: None.
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
ITEM 8.01 OTHER EVENTS.
On April 6, 2026, Adaptin Bio, Inc. announced that its common shares
have been approved for quotation on the OTCQB® Venture Market under the ticker symbol APTN. A copy of the press release is attached
hereto as Exhibit 99.1 and is incorporated herein by reference.
ITEM
9.01 FINANCIAL STATEMENTS AND EXHIBITS.
(d) Exhibits
| Exhibit No. |
|
Description |
| 99.1 |
|
Press release, dated April 6, 2026. |
| 104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
Adaptin Bio, Inc. |
| |
|
|
| Date: April 6, 2026 |
By: |
/s/ Michael J. Roberts |
| |
|
Michael J. Roberts |
| |
|
President and Chief Executive Officer |
Exhibit 99.1
Adaptin Bio Shares
to be Quoted on the OTCQB Under Ticker Symbol APTN
CHARLOTTE, N.C.—
April 6, 2026—Adaptin Bio, Inc. (OTCQB: APTN), (“Adaptin” or the “Company”), a biotechnology company developing
precision cancer therapeutics enabled by targeted delivery to the brain and other difficult-to-reach tissues, today announced that its
common shares have been approved for quotation on the OTCQB® Venture Market under the ticker symbol APTN. Quotation on
the OTCQB is expected to provide greater access to U.S. investors, improve liquidity, and enhance visibility within the investment community.
The Company expects trading to begin approximately within the next 6-8 weeks and will provide any material updates as they become available.
“We are extremely pleased to have our shares approved for quotation
on the OTCQB as part of the execution of our business plan. The pending quotation will provide more investors the ability to participate
in Adaptin’s mission to advance our novel CNS-targeted therapies for difficult-to-treat cancers,” said Michael J. Roberts,
Ph.D., Chief Executive Officer of Adaptin Bio. “Importantly APTN-101, our lead program that is expected to begin a Phase
1 first-in-human clinical trial shortly, leverages our BRiTE antibody delivery platform, and has demonstrated compelling anti-tumor activity
and a favorable safety profile in multiple preclinical models. APTN-101 has the potential to meaningfully improve the lives of patients
suffering from a variety of devastating diseases, and we are focused on advancing this compound through clinical trials and bringing it
to patients as rapidly as possible.”
About APTN-101 BRiTE Therapeutic
Adaptin Bio’s proprietary brain bispecific T cell engager, APTN-101,
leverages the enhanced “hitchhiking” capabilities of manipulated immune cells to deliver therapeutic agents directly to brain
tumors. The novel approach has demonstrated high specificity for EGFRvIII-expressing glioma cells, dose-responsive efficacy against diverse
patient-derived glioma cell lines, and a favorable safety profile. By manipulating the immune system either in vivo or ex vivo, BRiTE
aims to overcome traditional treatment barriers and offer a promising new therapeutic option for patients with intracerebral malignancies.
About Adaptin Bio, Inc.
Adaptin Bio, Inc. is a biotechnology company developing novel therapies
for oncology and central nervous system disorders. Its mission is to improve patient outcomes in difficult-to-treat cancers by improving
and enhancing drug delivery to the brain and other tissues. The Company’s proprietary Brain Bispecific T cell Engager (BRiTE) technology
was developed by researchers at the Department of Neurosurgery at Duke University. APTN-101 is FDA-cleared for a Phase 1 clinical trial
in glioblastoma (GBM), and other indications are being considered for future studies. For more information, visit www.adaptinbio.com.
Caution Regarding Forward
Looking Statements:
Except for historical information, all of the statements, expectations
and assumptions contained in this press release are forward-looking statements. These forward-looking statements may include information
concerning possible or projected future business operations. Such statements are often characterized by the use of qualified words (and
their derivatives) such as “aims,” “anticipate,” “believe,” “continues,” “could,”
“design,” “estimate,” “expect,” “goals,” “intend,” “looking,”
“may,” “objectives,” “opportunity,” “outlook,” “plan,” “positioned,”
“potential,” “project,” “seek,” “should,” “target,” “will,” “would,”
or other statements concerning opinions or judgments of the Company and its management about future events. Actual results might differ
materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ
materially include: our ability to raise additional money to fund our operations for at least the next 12 months as a going concern and
develop our product candidate as anticipated; our ability to control costs associated with our operations; intellectual property risks;
risks of our clinical trials, including, but not limited to, the timing, delays, costs, design, initiation, enrollment, and results of
such trials; any delays in regulatory review and approval of product candidates in development; reliance on third parties to supply drug
substance and drug product for our clinical trials and preclinical studies, and produce commercial supplies of product candidates; the
potential advantages of our product candidate; our competitive position; risks related to our ability to initiate trading and develop
a market for common stock; our ability to maintain our culture and recruit, integrate and retain qualified personnel and advisors, including
on our Board of Directors; volatility and uncertainty in the global economy and financial markets; changes in legal, regulatory and legislative
environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products;
and other risks and uncertainties set forth from time to time in our filings with the Securities and Exchange Commission. Adaptin assumes
no obligation and does not intend to update these forward-looking statements except as required by law.
Investor Contact:
1-800-428-8070
investor@adaptinbio.com
